Exelixis (EXEL) Depreciation & Amortization (CF) (2010 - 2026)
Exelixis' (EXEL) quarterly Depreciation & Amortization (CF) came in at $6.9 million in Q2 2026, down 5.41% year-on-year from $7.3 million in Q2 2025, and little changed quarter-over-quarter from $6.9 million in Q1 2026.
Exelixis (EXEL) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Exelixis' Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $6.9 million for Q2 2026.
- On a quarterly basis, Depreciation & Amortization (CF) fell 5.41% year-over-year to $6.9 million in Q2 2026; TTM through Apr 2026 was $28.7 million, a 3.74% decrease from a year earlier, with the FY2026 full-year figure at $29.1 million, up 0.87% from the prior year.
- Depreciation & Amortization (CF) was little changed at $6.9 million in Q2 2026 per EXEL's latest filing, from $6.9 million in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $7.6 million in Q1 2025 and bottomed at $4.5 million in Q2 2022.
- The 5-year median for Depreciation & Amortization (CF) is $6.9 million (2023), against an average of $6.6 million.
- Across the five-year window, Depreciation & Amortization (CF) soared 207.92% in 2022 and retreated 9.11% in 2026, its largest moves.
- Year by year, Depreciation & Amortization (CF) stood at $5.9 million in 2022, then increased by 9.75% to $6.5 million in 2023, then advanced by 14.22% to $7.5 million in 2024, then retreated by 0.43% to $7.4 million in 2025, then fell by 6.39% to $6.9 million in 2026.
- Per Business Quant, the three latest EXEL Depreciation & Amortization (CF) figures stand at $6.9 million (Q2 2026), $6.9 million (Q1 2026), and $7.4 million (Q4 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Exelixis | 14.38 Bn | 13.60 Bn | 590.86 Mn | 6.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 6.95 Mn |
| Apr 3, 2026 | 6.95 Mn |
| Jan 2, 2026 | 6.95 Mn |
| Jan 2, 2026 | 6.95 Mn |
| Oct 3, 2025 | 7.42 Mn |
| Oct 3, 2025 | 7.42 Mn |
| Jul 4, 2025 | 7.34 Mn |
| Jul 4, 2025 | 7.34 Mn |
| Apr 4, 2025 | 7.35 Mn |
| Apr 4, 2025 | 7.35 Mn |
| Jan 3, 2025 | 7.64 Mn |
| Jan 3, 2025 | 7.64 Mn |
| Sep 27, 2024 | 7.45 Mn |
| Sep 27, 2024 | 7.45 Mn |
| Jun 28, 2024 | 7.33 Mn |
| Jun 28, 2024 | 7.33 Mn |
| Mar 29, 2024 | 6.38 Mn |
| Mar 29, 2024 | 6.38 Mn |
| Dec 29, 2023 | 6.53 Mn |
| Dec 29, 2023 | 6.53 Mn |